Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review

摘要: We analyzed clinical trials of low dose cytosine arabinoside (LDARA-C) in 324 patients with acute myelogenous leukemia (AML) and 129 myelodysplasia (MDS). Complete partial remission rates were 31% 18%, respectively, AML, 24% 27% MDS. Toxicity was primarily hematologic. Although vitro data suggested that LDARA-C acts as a differentiating agent, generally indicate cytotoxic mechanism. Given the lack effective therapeutic options MDS high risk AML (patients greater than 65 years old, secondary AML), these are encouraging. warrants further study, comparing continuous infusion intermittent subcutaneous administration to conventional therapy.